AVEIR™ Leadless Pacemaker Registry in Europe and MIddle East Region
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 1,698
- 主要终点
- The primary safety endpoint is 1 year incidence rate of leadless device-related or procedure-related major complications. AveirTM LP systems
研究概览
简要总结
The AVEIR™ Leadless Pacemaker Registry (herein referred to as "PREMIER LEADLESS Registry") is a prospective, multicenter, International, open label observational study designed to evaluate safety and electrical performances of AVEIR™ leadless pacemakers used in real-world clinical practice and to evaluate clinical outcomes and characteristics of patients treated with these leadless devices.
详细描述
The AVEIR™ Leadless Pacemaker Registry (herein referred to as "PREMIER LEADLESS Registry") is a prospective, multicenter, International, open label observational study designed to evaluate safety and electrical performances of AVEIR™ leadless pacemakers used in real-world clinical practice and to evaluate clinical outcomes and characteristics of patients treated with these leadless devices. The study aims to evaluate safety profile, electrical performances and clinical outcomes in patients indicated for cardiac pacing after they receive Aveir LP systems. The Aveir VR LP system, for ventricular pacing, and the Aveir AR LP system for atrial pacing, and their concomitant use in the dual chamber configuration (Aveir DR LP system), have received the CE mark. The study also aims to understand clinical characteristics of patients receiving AVEIR™ leadless pacemaker devices in real-world clinical practice. The study Investigators will gather data from routine hospital practices and standard-of-care (SOC) procedures administered to patients. All devices used in these procedures are commercially available and already in use in the participating sites. The structure of this document provides a general overview and methodology of the study and a few specific details such as sample size, follow-up procedures, reporting requirements, and definitions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has clinical indication to cardiac pacing in adherence with ESC cardiac pacing guidelines.
- •Subject is ≥ 18 years of age or age of legal consent, whichever age is greater.
- •Subject agrees to return to clinic for the study follow-up visits.
- •Subject has been informed of the nature of the study, agrees to its provisions and has provided a signed written informed consent, approved by IRB/EC.
排除标准
- •Subject is currently participating in another study that may confound the results of this research.
- •Subject has a life expectancy less than 12 months.
- •Subject is pregnant or nursing or planning pregnancy during the study.
- •Subject has anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the study or to comply with the site standard follow-up visits, for example a mechanical tricuspid
- •Page 3 of 4 [DRAFT] - valve prosthesis or vein thrombosis, which could impede the delivery of implantable devices as planned by the implanters.
- •Subject is allergic/hypersensitive to <1 mg dexamethasone sodium phosphate.
- •Subject is implanted with an electrically active implantable medical device with stimulation capabilities at risk to be impacted by the Aveir Link Module telemetry.
- •Subject has known pacemaker syndrome, if that condition, in the investigator's opinion, represents a contraindication to the implant of the planned pacemaker.
- •Subject has pacing induced cardiomyopathy.
结局指标
主要结局
The primary safety endpoint is 1 year incidence rate of leadless device-related or procedure-related major complications. AveirTM LP systems
时间窗: 12 momths
Major complications are defined as events related to the leadless pacing system or leadless pacing system implant procedure resulting in death, permanent loss of device function due to mechanical or electrical dysfunction, hospitalization, prolonged hospitalization by at least 48 h, or system revision AveirTM LP systems
Acceptable ventricular pacing thresholds and R-wave amplitudes measured at 12 months.
时间窗: 12 months
Ventricular pacing threshold is considered acceptable if \<2.0 V at 0.4 ms and R-wave amplitude is considered acceptable if \>5.0 mV or ≥ of the implant value
Acceptable atrial pacing thresholds and P-wave amplitudes as measured at 12 months.
时间窗: 12 months
atrial capture threshold is considered acceptable if ≤3.0 V at 0.4 ms and atrial sensing Amplitude is considered adequate if P wave ≥1.0 mV.
次要结局
- Final LP placement site.(24 months)
- Device longevity, as displayed by the programmer at each visit.(48 months)
- Device programming and pacing and sensing conditions which may impact longevity.(48 months)
- Need for and success of device retrieval.(48 months)
- Development of pacing induced cardiomyopathy(48 months)
- Number of hospitalizations and mortality.(48 months)
- Implant duration, fluoroscopy duration, and time from implant to hospital discharge.(24 months)
- Demographics and medical history, with specific focus on indication for pacemaker implant and reasons for the choice of leadless pacemakers.(24 months)
- Number of device repositioning at time of implantation.(24 months)
- Freedom from device- or procedure-related major complications at 24 months(24 months)
- All adverse events, regardless device- or procedure-relatedness.(48 months)
- Implant success rate and reasons for unsuccessful implant.(24 months)
- Upgrade from Aveir VR to Aveir DR and from Aveir AR to Aveir DR.and Communication i2i success rate.(48 months)
研究者
Fayez Bokhari
Medical Director - Head of Cardiology
King Fahad Armed Forces Hospital